IN185276B - - Google Patents
Info
- Publication number
- IN185276B IN185276B IN1579DE1996A IN185276B IN 185276 B IN185276 B IN 185276B IN 1579DE1996 A IN1579DE1996 A IN 1579DE1996A IN 185276 B IN185276 B IN 185276B
- Authority
- IN
- India
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US145395P | 1995-07-17 | 1995-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN185276B true IN185276B (US07851000-20101214-C00005.png) | 2000-12-16 |
Family
ID=21696097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1579DE1996 IN185276B (US07851000-20101214-C00005.png) | 1995-07-17 | 1996-07-16 |
Country Status (38)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| IN191236B (US07851000-20101214-C00005.png) | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
| US6646133B1 (en) | 2000-10-17 | 2003-11-11 | Egis Gyogyszergyar Rt. | Process for the preparation of amorphous atorvastatin calcium |
| HU226640B1 (en) * | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| ES2313999T3 (es) * | 2000-11-16 | 2009-03-16 | Teva Pharmaceutical Industries Ltd. | Hidrolisis de esteres del acido (r(r*,r*))-2-(4-fluorofenil)-beta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)-1h-pirrol-1-heptanoico con hidroxido calcico. |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| ATE420070T1 (de) | 2000-12-27 | 2009-01-15 | Teva Pharma | Kristalline formen von atorvastatin |
| WO2002057228A1 (en) * | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| SI20814A (sl) * | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
| SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| IN190564B (US07851000-20101214-C00005.png) * | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| EE200300597A (et) * | 2001-06-29 | 2004-02-16 | Warner-Lambert Company Llc | [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[fenüülamino)karbonüül]-1H-pürrool-1-hepta anhappe kaltsiumsoola (2:1) (atorvastatiini) kristallilised vormid |
| US7361772B2 (en) | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
| CA2456095C (en) | 2001-08-31 | 2010-05-11 | Morepen Laboratories Ltd. | An improved process for the preparation of amorphous atorvastatin calcium salt (2:1) |
| UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
| CZ296967B6 (cs) | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
| ATE452871T1 (de) | 2002-03-18 | 2010-01-15 | Biocon Ltd | Amorphe hmg-coa-reduktase-inhibitoren mit gewünschter teilchengrösse |
| ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
| AU2002356423A1 (en) * | 2002-05-28 | 2003-12-12 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| US7179942B2 (en) | 2002-07-05 | 2007-02-20 | Bicon Limited | Halo-substituted active methylene compounds |
| EP1562583A1 (en) * | 2002-09-03 | 2005-08-17 | Morepen Laboratories Ltd. | Atorvastatin calcium form vi or hydrates thereof |
| BRPI0409292A (pt) | 2003-04-11 | 2006-04-11 | Lek Pharmaceuticals | processo para a preparação de sal de cálcio amorfo de atorvastatina |
| AU2003231926A1 (en) | 2003-04-22 | 2004-11-19 | Biocon Limited | NOVEL PROCESS FOR STEREOSELECTIVE REDUCTION OF ss-KETOESTERS |
| US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| US7557238B2 (en) | 2003-09-18 | 2009-07-07 | Biocon Limited | Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
| CA2456430A1 (en) * | 2004-01-28 | 2005-07-28 | Brantford Chemicals Inc. | Improved process for the preparation of amorphous atorvastatin calcium |
| CZ298382B6 (cs) * | 2004-03-10 | 2007-09-12 | Zentiva, A. S. | Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace |
| CA2627940A1 (en) | 2004-03-17 | 2005-10-06 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form |
| EP1745020A2 (en) | 2004-05-05 | 2007-01-24 | Pfizer Products Incorporated | Salt forms of atorvastatin |
| JP5000502B2 (ja) * | 2004-07-16 | 2012-08-15 | レツク・フアーマシユーテイカルズ・デー・デー | アトルバスタチンカルシウムの酸化分解生成物 |
| JP2008510798A (ja) | 2004-08-27 | 2008-04-10 | バイオコン・リミテッド | 非晶質アトルバスタチンカルシウムのための方法 |
| EP1793815A4 (en) * | 2004-09-30 | 2010-12-29 | Reddys Lab Ltd Dr | AMORPHES ATORVASTATINCALCIUM |
| TW200942516A (en) * | 2004-10-18 | 2009-10-16 | Teva Pharma | Processes for preparing amorphous atorvastatin hemi-calcium |
| BRPI0519996A2 (pt) * | 2004-10-28 | 2009-04-07 | Warner Lambert Co | processo para formar atorvastatina amorfa |
| AU2005305460B2 (en) * | 2004-11-22 | 2011-04-21 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| EP1819319A1 (en) * | 2004-12-02 | 2007-08-22 | Warner-Lambert Company LLC | Pharmaceutical compositions of amorphous atorvastatin and process for preparing same |
| US20080108664A1 (en) * | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| CA2640573A1 (en) * | 2006-03-01 | 2007-09-13 | Michael Pinchasov | Process for preparing a crystalline form of atorvastatin hemi-calcium |
| US20100113802A1 (en) * | 2006-11-02 | 2010-05-06 | Cadila Pharmaceuticals Limited | Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate |
| US7834195B2 (en) | 2007-01-24 | 2010-11-16 | Apotex Pharmachem Inc. | Atorvastatin calcium propylene glycol solvates |
| EP2185527A2 (en) * | 2007-07-11 | 2010-05-19 | Actavis Group PTC EHF | Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium |
| US20090124817A1 (en) * | 2007-11-09 | 2009-05-14 | The Industry & Academic Cooperation In Chungnam National University | Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles |
| EP2075246A1 (en) | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
| WO2010066846A2 (en) * | 2008-12-11 | 2010-06-17 | Dsm Ip Assets B.V. | Method for the isolation of atorvastatin |
| EP2373609B1 (en) | 2008-12-19 | 2013-10-16 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
| EP2327682A1 (en) | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
| CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| WO1997003959A1 (en) | 1995-07-17 | 1997-02-06 | Warner-Lambert Company | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
-
1996
- 1996-07-03 HR HR960312A patent/HRP960312B1/xx not_active IP Right Cessation
- 1996-07-16 MX MX9708959A patent/MX9708959A/es unknown
- 1996-07-16 PL PL324463A patent/PL191017B1/pl unknown
- 1996-07-16 SI SI9630284T patent/SI0839132T1/xx unknown
- 1996-07-16 DE DE69611999T patent/DE69611999T2/de not_active Revoked
- 1996-07-16 WO PCT/US1996/011807 patent/WO1997003960A1/en not_active Application Discontinuation
- 1996-07-16 CA CA002220455A patent/CA2220455C/en not_active Expired - Lifetime
- 1996-07-16 CZ CZ1998122A patent/CZ289421B6/cs not_active IP Right Cessation
- 1996-07-16 NZ NZ313008A patent/NZ313008A/xx not_active IP Right Cessation
- 1996-07-16 HU HU9903017A patent/HU220343B/hu unknown
- 1996-07-16 SK SK58-98A patent/SK283204B6/sk not_active IP Right Cessation
- 1996-07-16 ES ES96924553T patent/ES2156997T3/es not_active Expired - Lifetime
- 1996-07-16 AT AT96924553T patent/ATE199542T1/de not_active IP Right Cessation
- 1996-07-16 PT PT96924553T patent/PT839132E/pt unknown
- 1996-07-16 CN CN96195631A patent/CN1087289C/zh not_active Expired - Lifetime
- 1996-07-16 JP JP50681497A patent/JP4064459B2/ja not_active Expired - Lifetime
- 1996-07-16 GE GEAP19964149A patent/GEP20002027B/en unknown
- 1996-07-16 KR KR10-1998-0700348A patent/KR100400805B1/ko not_active IP Right Cessation
- 1996-07-16 AU AU64978/96A patent/AU700794B2/en not_active Expired
- 1996-07-16 EA EA199800128A patent/EA000625B1/ru not_active IP Right Cessation
- 1996-07-16 IN IN1579DE1996 patent/IN185276B/en unknown
- 1996-07-16 IL IL12216196A patent/IL122161A/xx not_active IP Right Cessation
- 1996-07-16 EE EE9700369A patent/EE03605B1/xx unknown
- 1996-07-16 AR ARP960103599A patent/AR002849A1/es not_active Application Discontinuation
- 1996-07-16 UA UA98020823A patent/UA50743C2/uk unknown
- 1996-07-16 RO RO98-00060A patent/RO120069B1/ro unknown
- 1996-07-16 EP EP96924553A patent/EP0839132B1/en not_active Revoked
- 1996-07-16 DK DK96924553T patent/DK0839132T5/da active
- 1996-07-16 BR BR9609714A patent/BR9609714A/pt not_active Application Discontinuation
- 1996-07-17 ZA ZA9606043A patent/ZA966043B/xx unknown
- 1996-07-17 PE PE1996000541A patent/PE1698A1/es not_active IP Right Cessation
- 1996-07-17 UY UY24286A patent/UY24286A1/es not_active IP Right Cessation
- 1996-07-17 CO CO96037512A patent/CO4700441A1/es unknown
-
1998
- 1998-01-14 BG BG102188A patent/BG63631B1/bg unknown
- 1998-01-16 NO NO980209A patent/NO309322B1/no unknown
- 1998-12-15 HK HK98113382A patent/HK1018054A1/xx not_active IP Right Cessation
-
2000
- 2000-09-07 US US09/657,469 patent/US6274740B1/en not_active Expired - Lifetime
-
2001
- 2001-05-15 GR GR20010400710T patent/GR3035859T3/el not_active IP Right Cessation
